Senescent Cells Evade Iron-Driven Death Via Faulty Lysosomes
Alkalinized lysosomes in senescent cells trap iron, blocking ferroptosis. Restoring lysosomal acidity with EN6 reverses resistance in aging and cancer.
Summary
Senescent cells accumulate iron yet resist ferroptosis, a form of iron-dependent cell death. Researchers discovered that lysosomal alkalinization — a hallmark of cellular senescence — traps ferrous iron inside lysosomes, preventing it from driving lipid peroxidation in the cytoplasm and membranes. Restoring lysosomal acidity with EN6, a V-ATPase activator, re-sensitized senescent cells to ferroptosis. The same mechanism was found in ferroptosis-resistant pancreatic cancer cells. EN6 treatment suppressed pancreatic cancer growth in both xenograft and Kras mutant mouse models, suggesting lysosomal re-acidification as a dual strategy against senescence-driven aging disease and therapy-resistant cancers.
Detailed Summary
Senescent cells are well known to accumulate in aging tissues and drive chronic inflammation, yet they stubbornly resist most forms of cell death — including ferroptosis, a process fueled by iron-dependent lipid peroxidation. Understanding why could unlock new senolytic strategies that selectively clear senescent cells without harming healthy tissue.
This study, conducted in human diploid fibroblasts (TIG-3) rendered senescent by X-ray irradiation or replicative passaging, systematically dissected the ferroptosis pathway in senescent versus normal cells. Despite harboring elevated levels of labile ferrous iron (Fe²⁺) and baseline reactive oxygen species (ROS), senescent cells failed to undergo lipid peroxidation or cell death when cystine was depleted via erastin or cystine-free medium. Glutathione (GSH) depletion occurred similarly in both cell types upon erastin treatment, ruling out antioxidant buffering as the resistance mechanism. Instead, the block resided upstream: lipid peroxidation itself was suppressed in senescent cells.
Using global redox phospholipidomic LC/HRMS/MS analysis, the team found that senescent cells exhibited altered lipid profiles, with insufficient oxidation of polyunsaturated fatty acid-containing phosphatidylcholines (PC-PUFAs) after erastin treatment. Crucially, live-cell imaging with lysosome-targeted iron probes revealed that ferrous iron was aberrantly sequestered inside alkalinized lysosomes of senescent cells rather than distributing to the cytoplasm and membranes where it would normally catalyze Fenton-type lipid peroxidation. Lysosomal alkalinization — a well-documented feature of senescent cell biology — was identified as the root cause: without acidic pH, lysosomes cannot properly process and release iron, leaving it compartmentalized and inert with respect to membrane lipid oxidation.
To rescue ferroptosis sensitivity, the researchers treated senescent cells with EN6, a small-molecule activator of the vacuolar H⁺-ATPase (V-ATPase) proton pump that acidifies lysosomes. EN6 restored lysosomal acidity, re-mobilized ferrous iron to the cytoplasm, rescued lipid peroxidation, and re-sensitized senescent cells to ferroptosis. Remarkably, the same lysosomal alkalinization and ferroptosis-resistance phenotype was identified in multiple pancreatic cancer cell lines known to be resistant to chemotherapy and radiotherapy. EN6 treatment significantly suppressed tumor growth in both human pancreatic cancer xenograft models and genetically engineered Kras mutant mice that spontaneously develop pancreatic ductal adenocarcinoma.
These findings establish lysosomal acidity as a critical gatekeeper of ferroptosis sensitivity, reveal a shared resistance mechanism between senescent cells and therapy-resistant cancers, and position V-ATPase activators like EN6 as candidate senolytics and anti-cancer agents. Caveats include reliance on cell-line and mouse models, the need for pharmacokinetic optimization of EN6 in humans, and the question of whether lysosomal re-acidification may have off-target effects on normal cell physiology at therapeutic doses.
Key Findings
- Lysosomal alkalinization in senescent cells traps ferrous iron, blocking cystine-deprivation-induced lipid peroxidation and ferroptosis.
- Senescent cells show elevated Fe²⁺ and ROS yet resist erastin-induced ferroptosis; GSH depletion occurs normally, ruling it out as the mechanism.
- V-ATPase activator EN6 restored lysosomal acidity, redistributed iron, and re-sensitized senescent cells to ferroptosis.
- Pancreatic cancer cell lines share the same lysosomal alkalinization-based ferroptosis resistance mechanism.
- EN6 suppressed pancreatic tumor growth in xenograft and Kras mutant mouse models.
Methodology
Human diploid TIG-3 fibroblasts were rendered senescent by X-ray irradiation or replicative passaging, then assessed for ferroptosis sensitivity using viability, LDH release, C11-BODIPY lipid peroxidation, and global redox phospholipidomic LC/HRMS/MS analyses. Cancer relevance was validated in pancreatic cell lines, subcutaneous xenograft models, and Kras-driven transgenic mice treated with the V-ATPase activator EN6.
Study Limitations
All mechanistic experiments were performed in cell lines and mouse models; human clinical validation is absent. EN6's pharmacokinetics, bioavailability, and potential toxicity to normal tissues via lysosomal re-acidification have not been fully characterized. The study focused on cystine-deprivation ferroptosis; whether other ferroptosis inducers are similarly affected by lysosomal status requires further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.